Companies

Akebia Therapeutics, Inc. (AKBA) SEC filings

CIK 0001517022 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2023FY2021FY2020
Revenue (USD)236.2 M292.5 M
Net income (USD)-279.7 M-143.6 M
Diluted EPS (USD/shares)-0.02-0.52

Latest filings

FiledFormDescriptionPeriod
2026-10-148-K8-K items 5.022026-10-07
2026-08-104PRIMARY DOCUMENT2026-08-06
2026-08-05S-8S-8
2026-08-0510-Q10-Q2026-06-30
2026-08-058-K8-K items 2.02,9.012026-08-05
2026-07-014PRIMARY DOCUMENT2026-06-29
2026-06-308-K8-K items 7.01,8.01,9.012026-06-30
2026-06-29144144
2026-06-224PRIMARY DOCUMENT2026-06-17
2026-06-224PRIMARY DOCUMENT2026-06-17
2026-06-224PRIMARY DOCUMENT2026-06-17
2026-06-224PRIMARY DOCUMENT2026-06-17
2026-06-228-K8-K items 5.072026-06-17
2026-06-224PRIMARY DOCUMENT2026-06-17
2026-06-224PRIMARY DOCUMENT2026-06-17
2026-05-12SCHEDULE 13GSCHEDULE 13G
2026-05-0710-Q10-Q2026-03-31
2026-05-078-K8-K items 2.02,9.012026-05-07
2026-04-29ARSARS2025-12-31
2026-04-28DEFA14ADEFA14A
2026-04-28DEF 14ADEF 14A2026-04-28
2026-04-15PRE 14ADEF 14A2026-04-15
2026-04-034PRIMARY DOCUMENT2026-04-01
2026-04-033PRIMARY DOCUMENT2026-04-01
2026-04-018-K8-K items 5.02,9.012026-03-27

Forms on file (last 1,000): 4 326, 8-K 164, 3 42, 10-Q 38, SC 13G/A 37, 144 28, 425 25, DEFA14A 22. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=AKBA (0.002 USD), /gw/filings/filings?ticker=AKBA&form=8-K, /gw/filings/facts?ticker=AKBA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange